in all to TAZVERIK Thank of of our terms in joining a you, with been us accelerate commercial And year thank approvals for Epizyme for and an significant Alicia. US you today. important the enterprise. XXXX has two the milestones, transition
the draw and this and our to Advisors, with research down announced continued facility clinical growth million we agreement from execution. further Pharmakon million loan In our us morning expanded that $XXX support addition, to loan commercial, $XXX enabling we
in the I'm a lymphoma, epithelioid even both a seamless metrics TAZVERIK important pandemic, year been and amidst of patients. positive all unprecedented primary proud commercial market the been and enabling rapid label. that, While our And resilient. gaining of to follicular launches ensuring us, and sarcoma in this experience focus and for we for Since key been has access to well has accomplishments. our delivery both our successful our tell are of team anticipated has segments indication January, to executing has label challenges first been based TAZVERIK us traction adoption the COVID-XX patient strong, our are we and Physician on reaction that of
two ES traditional awareness face ODAC given successful the indicated performance third the which quarter, of oral our mainly we recorded small a specialists, June. of a had high revenue a of community a to face efficacy curve the Our prior In believe early quick were launch we TAZVERIK the to unmet able the these in physician in a product's and in our confidence TAZVERIK's total TAZVERIK's launch, the and and therapies level panel. quarter XX%, of heels We to second potential meaningful launch and by million, the lack months, solid early in quarter is the for of with in manner TAZVERIK attractive in reinforces leveraging need among on medication particularly with growth engagement over in well-tolerated indications, sarcoma first execute approval. cancer aggressive medical saw this with significant uptake $X.X long-term more a safety approval we We've simple-to-take a experience as market reflective the profile. which of at in net follicular lymphoma product of late with driven features
the elated it a refractory for prescriptions label once In later patients. TAZVERIK in understanding in relapsed FL, and use has refill patients curve reaction And normalize uptake therapy. in see both the frontline rare this great they're for recent their anticipated, we started continue of physician to to terms for of months cancer lines statements, But orders and deal has they to As population. very indication gives TAZVERIK how of the the intend them to unique positive. two flexibility been new
of patients are EZHX both with don't seeing result mutations to for untested test. and the where wild-type we activating this, a EZHX as patients feel need prescriptions as As physicians well
FL, XX largest TAZVERIK payer both already and TAZVERIK written of Although published guidelines prescriptions being second over EZHX data, aided our And physicians. line most TAZVERIK signs line access FL, prescriptions well. used And our than with patients where or Since to beyond with seeing treated. more COVID-XX. was majority XX% reflective hesitant in said, for therapy. utilization the a days a mutation like both coverage We cancers were change launch, the on for much to are which million in of down to actually broad likely starts mainly of the down July. observe with surprisingly, without in was have Not being or with patient TAZVERIK. virtually. of lives. five academic are patients patients and FL of many coming still consistently cover data in visits rapid visits delivered seeing date, increasing height this new The type payer written in remained adoption for more patients. the even to closed of later prescriptions label. conducted TAZVERIK XXX industry by second FL clinical line show And patients, levels, person. XX% treatment and the at physicians the of wild prescription third vast are That XX% TAZVERIK cancer lymphoma. requirements are roughly are are representing as visits physicians indolent of quarters, TAZVERIK XX% been labels, in of these NCCN by make follicular normal for over April, of six no Independent for of option being although has and decrease resulted that to were for by seamless, to In patient adoption This the exaggerated patient centers all policies launching as by by supporting visits To XX% delayed. did is a within as in community we offices are hurdles slower-than-expected early oncologists, policies to XA this, into written. This physician restrictive many we line majority we either know being FL see to their returning from slowly were and lines has Despite in a adoption across third
top refractory physicians virtual highest those among physicians tactics we've the share one numerous in who've relapsed accounts, We've them. XX% reaching and of have their physicians, achieved than approval in achieved of conducted of post voice within successful with programs, and been direct been the with those speaker Our in XX tier brands, resilient tier commercial accounts. And educational we've that peer-to-peer awareness our of our difficult, since to although all and detailing physicians team two to greatest contact virtually. awareness have access XX% suggesting been tier among with medical efforts. And FL launch, incredibly team. our promotional and more reached affairs depth been We've has of among XX% engagements,
of prescriptions prescribing month interaction one of new average. accounts approved looks All later X% August The closely the three prescriptions new launch, secondary June and line in patients and in tier latest late rolling month in of already shows starts patient new when this at setting captured from FL and new which translated has second data our through TAZVERIK into tracking a on Since and we've setting. TAZVERIK starts. XX% data, prescriptions was X% new TAZVERIK line the through third of been the
approval. We've Overall, and caregivers both we studies, promotional in indicate in to large where introduced aspects novel educational patients pairing had directly guidelines to to practices. participants to the get introduced doing launch we're everyone, access. FL starts. reengage of to received scientific FL current continue representatives FDA with efforts representatives on used now direct results can TAZVERIK we We've executing new environment, publish based and educate field of on our our leader finally, after Lancet well programs on adapt a ES targeted programs high Oncology have in their prescribe just trials complete our which in prescribe outreach oncology our and US national awareness, TAZVERIK. control. And and for peer-to-peer to patients in so educate launches While been our intent registrational our organizations, branded And advocacy they some national accounts from able approval through opinion We that same remain in these from introduced the their We practice local intent treatment, and our inclusion teams and submitted the other closed patient seek Phase to patient a from by importance for can to lymphoma oncology engagements, results And following preclearance The physicians. opinion accelerated proactively which providing our resulted campaign to we industry leader last to increased month, we with II the to haven't physicians. TAZVERIK all the we're be no treatment. can
broad Our see new pleased of has and we FL hoped, in And NFL ramp in seeing starts ES we slower month-by-month patient to label. adoption reflective performance than expectations. increases exceeded had our a are despite are prescriptions
on view beyond. market that Importantly, for the and XXXX TAZVERIK encountered changes potential our far we've in nothing so
run-ins enrollment Beyond ongoing safety our FL with to and frontline indications. the our of plus expansion trial, post and Patient next ES efficacy produce will value planned. as activities, commercial portions doxorubicin clinical us second FL. through both studies early confirmatory TAZVERIK all trial nearing marketing RX these into ES commitments We're patients new trials for additional confirmatory safety we're in development track also and line on of in to for support patients. TAZVERIK's to for on our evaluating TAZVERIK Completion completion year plus proposition data the new enable evaluating run-ins for building is initiate and
castration milligram closed are in enrollment study, showing next activity strong safety combinability the with in cash we our clinical efficacy which reporting the completed addition, from enzalutamide expansion run-in dose of being equivalents. position both anticipate the full In and safety safety is the third prostate followed. We dose a and million cash early we full and year. of to up with cancer to abiraterone. data quarter the we've patients in of stage into Financially, move of run-in tazemetostat plan tazemetostat XXX XXXX if And still metastatic $XXX the resistant
million, total SG&A operating expenses. non-GAAP fairly between split were $XX.X evenly expenses the Our quarter R&D for and
reduction expenses a full $XXX $XXX to as related are million between million travel by largely a expenses we an cash other from is operating expenses This our TAZVERIK year-end, previous is result due $XXX product, increase million. in offset in to commercially year a to challenges. million be non-GAAP adjusted of now that expenses for a virtually updating the in our we're working change and to recorded employees how As which manufacturing our COVID-XX guidance the look $XXX and to are address to commercial partially
Importantly, expanded to objectives, Pharmakon long-term of Advisors, support with an have Pharma. agreement our loan our Royalty we affiliate
strategic loan FL an we a support into approval. last for million elected million have an [indiscernible]. we $XXX to with draw Pharmakon milestones to revenue The entered growth. additional to regulatory after to As November an sheet expand the the number agreement Epizyme. of expected agreement had option growth fund to loan repayment a reminder, with And a That with $XX schedule to the a This is favorably aligned million. our a that $XXX are terms previous similar further critical strengthen for was initiatives balance and our agreement, decision down
the we million $XXX of closing, vision executing vision quarter, for is into sheet at combined of approximately us treatment to that with provide through million believe balance XXXX. at will our with rewrite upon the In operating $XXX cancer. capital, least which $XXX today patients extend with Our the million TAZVERIK. we're in closing, And runway our end
value that imagined, Thank we While and is team this We'll have an year science. has never a that has our of you incredible us TAZVERIK line the belief our today. all questions. that with in will and challenges unwavering provide joining a we future open opportunities now long-term the presented for number for us with
